NO991701D0 - HIV og cancer behandling - Google Patents

HIV og cancer behandling

Info

Publication number
NO991701D0
NO991701D0 NO991701A NO991701A NO991701D0 NO 991701 D0 NO991701 D0 NO 991701D0 NO 991701 A NO991701 A NO 991701A NO 991701 A NO991701 A NO 991701A NO 991701 D0 NO991701 D0 NO 991701D0
Authority
NO
Norway
Prior art keywords
hiv
cancer treatment
cancer
treatment
Prior art date
Application number
NO991701A
Other languages
English (en)
Other versions
NO991701L (no
Inventor
James Berger Camden
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO991701D0 publication Critical patent/NO991701D0/no
Publication of NO991701L publication Critical patent/NO991701L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO991701A 1997-05-16 1999-04-09 HIV og cancer behandling NO991701L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4672697P 1997-05-16 1997-05-16
PCT/US1997/021564 WO1998051303A1 (en) 1997-05-16 1997-11-26 Hiv and cancer treatment

Publications (2)

Publication Number Publication Date
NO991701D0 true NO991701D0 (no) 1999-04-09
NO991701L NO991701L (no) 2000-01-17

Family

ID=21945046

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991701A NO991701L (no) 1997-05-16 1999-04-09 HIV og cancer behandling

Country Status (19)

Country Link
EP (1) EP0954309A1 (no)
JP (1) JP2000510156A (no)
KR (1) KR20000049064A (no)
CN (1) CN1254281A (no)
AR (1) AR009968A1 (no)
AU (1) AU7402998A (no)
BR (1) BR9712981A (no)
CA (1) CA2268848A1 (no)
CO (1) CO5070657A1 (no)
CZ (1) CZ124999A3 (no)
HU (1) HUP9904092A3 (no)
IL (1) IL129351A0 (no)
NO (1) NO991701L (no)
PE (1) PE11499A1 (no)
PL (1) PL335160A1 (no)
SK (1) SK46999A3 (no)
TR (1) TR199901530T2 (no)
WO (1) WO1998051303A1 (no)
ZA (1) ZA979095B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) * 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
WO2000050021A2 (en) * 1999-02-26 2000-08-31 Napro Biotherapeutics, Inc. Treatment regimen for prostate cancer, initiated after androgen ablative therapy has started
JP2002537328A (ja) * 1999-02-26 2002-11-05 ナプロ バイオセラピューティクス,インコーポレイテッド ホルモン感受性癌の治療レジメ
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
AU2001286744A1 (en) * 2000-08-25 2002-03-04 Beth Israel Deaconess Medical Center Compounds and methods for inhibiting neuronal cell death
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
AU9279601A (en) * 2000-09-26 2002-04-08 Procter & Gamble Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6407105B1 (en) * 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
WO2002041891A2 (en) * 2000-11-01 2002-05-30 The Procter & Gamble Company Hiv treatment with benzimidazoles
JP2004115397A (ja) * 2002-09-25 2004-04-15 Fuji Photo Film Co Ltd 血管疾患治療薬を含むリポソーム
WO2006060853A1 (en) * 2004-12-06 2006-06-15 Newsouth Innovations Pty Limited Treatment for cancer
AU2005313839B2 (en) * 2004-12-06 2010-03-11 Pitney Pharmaceuticals Pty Limited Treatment for cancer
US7727967B2 (en) * 2006-02-24 2010-06-01 Boise State University Cyanooxime inhibitors of carbonyl reductase and methods of using said inhibitors in treatments involving anthracyclines
WO2009043093A1 (en) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
CN101643729B (zh) * 2008-08-07 2011-12-28 复旦大学 核酸分子nrn1sr22及其在制备抗癌药物中的应用
US10435365B2 (en) 2014-03-16 2019-10-08 Hadasit Medical Research Services And Development Ltd. Type III deiodinase inhibitors and uses thereof
CN105418711A (zh) * 2015-11-06 2016-03-23 山东大学 一种α-L-鼠李糖苷酶在制备羟基脲糖苷衍生物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1090186C (zh) * 1993-03-31 2002-09-04 麦克公司 治疗aids药物组合物中的hiv蛋白酶抑制剂
US5656615A (en) * 1995-04-12 1997-08-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals
US5665713A (en) * 1995-04-12 1997-09-09 Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
TR199701151T1 (xx) * 1995-04-12 1998-03-21 The Procter & Gamble Company Vir�sler ve kanserlerin geli�mesini �nlemeye mahsus, N-klorofenil karbamatlar� ve N-klorofeniltiokarbamatlar� i�eren bir farmas�tik bile�im.
NZ503921A (en) * 1995-08-04 2002-03-01 Procter & Gamble Use of fluconazole mixed with chemotherapeutic agents for inhibiting the growth of cancers or tumors

Also Published As

Publication number Publication date
SK46999A3 (en) 2000-05-16
BR9712981A (pt) 2000-04-18
IL129351A0 (en) 2000-02-17
JP2000510156A (ja) 2000-08-08
EP0954309A1 (en) 1999-11-10
CZ124999A3 (cs) 1999-09-15
PE11499A1 (es) 1999-03-01
HUP9904092A2 (hu) 2000-04-28
ZA979095B (en) 1998-05-11
WO1998051303A1 (en) 1998-11-19
NO991701L (no) 2000-01-17
CA2268848A1 (en) 1998-11-19
CO5070657A1 (es) 2001-08-28
PL335160A1 (en) 2000-04-10
KR20000049064A (ko) 2000-07-25
CN1254281A (zh) 2000-05-24
HUP9904092A3 (en) 2000-07-28
AR009968A1 (es) 2000-05-17
AU7402998A (en) 1998-12-08
TR199901530T2 (xx) 1999-10-21

Similar Documents

Publication Publication Date Title
NO991701D0 (no) HIV og cancer behandling
ZA979096B (en) Viral and cancer treatment
NO20001307D0 (no) Cyklopentafenantreneyl-metallkomplekser og polymerisasjonsprosess
NO20000996L (no) Kombinasjonsterapi omfattende atorvastatin og et antihypertensivt middel
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
IS4481A (is) Díhýdrópyramídín og notkun þeirra
NO983266D0 (no) Distribuert Behandling
NO991150D0 (no) Pyrazolopyrimidiner og pyrazolotriaziner
IS5525A (is) Innúðabúnaður og aðferð
DK1454907T3 (da) Quninazolin og pyridopyrmidin-derivativer
NO20001488D0 (no) Forhåndsfylte ampuller og tilvirkning derav
DE69832657D1 (de) Empfangseinrichtungen und Empfangsverfahren
DE69835254D1 (de) Empfangseinrichtungen und Empfangsverfahren
ID24275A (id) Terapi kombinasi
NO983576D0 (no) Brönnbehandlingsfluider og fremgangsmåter
NO20005179D0 (no) Medikament behandling
NO20002189L (no) Anvendelse av makrolider for behandling av cancer og mukuladegenerasjon
NO972206D0 (no) Bjelke og karosserikonstruksjon
NO964541L (no) Porphacyanin og CNC-utvidete porphyriner
NO983263L (no) Distribuert behandling
NO20012738D0 (no) Terapeutiske produkter og anvendelse derav
DK1140952T3 (da) Phosphororganiske forbindelser og anvendelse heraf
DE69842206D1 (de) Echounterdrücker und echounterdrückungsverfahren
NO20003268L (no) Hyperhydrert kitikolin, fremgangsmÕte og anvendelse
NO985068L (no) Vaksiner for behandling av lymfom og leukemi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application